SCHEMBL1481855

SCHEMBL1481855

COc1ccc(CNC(=O)Cn2cc(-c3ccc(Cl)cc3Cl)nc2/C=C/c2ccc(-c3ccc(O)cc3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.56
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 5/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 3/20 0.40
RXFP1 Q9HBX9 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
KLK7 P49862 1/20 0.40
TP53 P04637 4/20 0.39
HSD17B10 Q99714 1/20 0.38
ARRB1 P49407 1/20 0.38
GNAQ P50148 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481859 1.00 CNR1 (0.56) CNR1KDM4EALDH1A1HTTMEN1
SCHEMBL1481827 0.90 CNR1 (0.44) CNR1MAPTRXFP1
SCHEMBL1481826 0.90 CNR1 (0.44) CNR1MAPTRXFP1
SCHEMBL1481991 0.90 CNR1 (0.54) CNR1RXFP1
SCHEMBL1481994 0.90 CNR1 (0.54) CNR1RXFP1
SCHEMBL1480464 0.89 CNR1 (0.53) CNR1KDM4EALDH1A1HTTMEN1
SCHEMBL1480466 0.89 CNR1 (0.53) CNR1KDM4EALDH1A1HTTMEN1
SCHEMBL1480569 0.89 CNR1 (0.51) CNR1KDM4EALDH1A1HTTMEN1
SCHEMBL1481109 0.89 CNR1 (0.51) CNR1KDM4EALDH1A1HTTMEN1
SCHEMBL1480567 0.89 CNR1 (0.51) CNR1KDM4EALDH1A1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ CNR1 3369/4885KDM4E 672/4885ALDH1A1 710/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ CNR1 3369/4885KDM4E 672/4885ALDH1A1 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.